[HTML][HTML] Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature

E Nikiphorou, H Radner, K Chatzidionysiou… - Arthritis research & …, 2016 - Springer
Patient-reported outcomes (PROs) reflect the patient’s perspective and are used in rheumatoid
arthritis (RA) routine clinical practice. Patient global assessment (PGA) is one of the most …

What causes hidradenitis suppurativa?—15 years after

…, Ł Matusiak, A Nassif, E Nikiphorou… - Experimental …, 2020 - Wiley Online Library
The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis
published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st International …

Rheumatoid arthritis and dietary interventions: systematic review of clinical trials

…, SD Petersson, C Rodomar, E Nikiphorou - Nutrition …, 2021 - academic.oup.com
Context The impact of various dietary interventions on rheumatoid arthritis (RA), characterized
by immune-inflammatory response, has been subject to increased attention. Objective A …

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

S Ramiro, E Nikiphorou, A Sepriano… - Annals of the …, 2023 - ard.bmj.com
Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR
recommendations for the management of axial spondyloarthritis (axSpA). Methods …

EULAR definition of difficult-to-treat rheumatoid arthritis

…, L Gutermann, Y Prior, E Nikiphorou… - Annals of the …, 2021 - ard.bmj.com
Background Despite treatment according to the current management recommendations, a
significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These …

[HTML][HTML] Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global …

…, APM Gomides, P Dieudé, E Nikiphorou… - Annals of the …, 2021 - ard.bmj.com
Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying
antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA). …

2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis

E Nikiphorou, EJF Santos, A Marques… - Annals of the …, 2021 - ard.bmj.com
Background An important but often insufficient aspect of care in people with inflammatory
arthritis (IA) is empowering patients to acquire a good understanding of their disease and …

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis

…, P van Riel, S Dumas, Y Prior, E Nikiphorou… - Annals of the …, 2022 - ard.bmj.com
Objective To develop evidence-based European Alliance of Associations for Rheumatology
(EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid …

A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome

S Norton, G Koduri, E Nikiphorou, J Dixey… - …, 2013 - academic.oup.com
Objectives. To study the prevalence at diagnosis and cumulative incidence of comorbidity in
RA, associations with clinical features and impact on outcome. Methods. Standard clinical, …

Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception …

P Kiely, AD Busby, E Nikiphorou, K Sullivan… - BMJ open, 2019 - bmjopen.bmj.com
Objectives To assess predictive factors for rheumatoid arthritis interstitial lung disease (RA-ILD)
in two early rheumatoid arthritis (RA) inception cohorts with a focus on methotrexate (…